Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Corrigendum: A Nanostructured Lipid System to Improve the Oral Bioavailability of Ruthenium(II) Complexes for the Treatment of Infections Caused by Mycobacterium tuberculosis.

da Silva PB, de Freitas ES, Solcia MC, de Souza PC, da Silva MM, Batista AA, Eismann CE, Rolisola AMCM, Menegário AA, Cardoso RF, Chorilli M, Pavan FR.

Front Microbiol. 2019 May 31;10:1213. doi: 10.3389/fmicb.2019.01213. eCollection 2019.

2.

Factors affecting the color stability and staining of esthetic restorations.

Schroeder T, da Silva PB, Basso GR, Franco MC, Maske TT, Cenci MS.

Odontology. 2019 Mar 28. doi: 10.1007/s10266-019-00421-x. [Epub ahead of print]

PMID:
30924033
3.

Intravaginal Delivery of Syngonanthus nitens (Bong.) Ruhland Fraction Based on a Nanoemulsion System Applied to Vulvovaginal Candidiasis Treatment.

Dos Santos Ramos MA, da Silva PB, de Toledo LG, Oda FB, da Silva IC, Dos Santos LC, Dos Santos AG, de Almeida MTG, Pavan FR, Chorilli M, Bauab TM.

J Biomed Nanotechnol. 2019 May 1;15(5):1072-1089. doi: 10.1166/jbn.2019.2750.

PMID:
30890237
4.

Repurposing strategies for Chagas disease therapy: the effect of imatinib and derivatives against Trypanosoma cruzi.

Simões-Silva MR, De Araújo JS, Peres RB, Da Silva PB, Batista MM, De Azevedo LD, Bastos MM, Bahia MT, Boechat N, Soeiro MNC.

Parasitology. 2019 Jul;146(8):1006-1012. doi: 10.1017/S0031182019000234. Epub 2019 Mar 12.

PMID:
30859917
5.

In vitro and in vivo anti-Helicobacter pylori activity of Casearia sylvestris leaf derivatives.

Spósito L, Oda FB, Vieira JH, Carvalho FA, Dos Santos Ramos MA, de Castro RC, Crevelin EJ, Crotti AEM, Santos AG, da Silva PB, Chorilli M, Bauab TM.

J Ethnopharmacol. 2019 Apr 6;233:1-12. doi: 10.1016/j.jep.2018.12.032. Epub 2018 Dec 27.

PMID:
30594606
6.

A Nanostructured Lipid System to Improve the Oral Bioavailability of Ruthenium(II) Complexes for the Treatment of Infections Caused by Mycobacterium tuberculosis.

da Silva PB, de Freitas ES, Solcia MC, de Souza PC, da Silva MM, Batista AA, Eismann CE, Rolisola AMCM, Menegário AA, Cardoso RF, Chorilli M, Pavan FR.

Front Microbiol. 2018 Dec 6;9:2930. doi: 10.3389/fmicb.2018.02930. eCollection 2018. Erratum in: Front Microbiol. 2019 May 31;10:1213.

7.

Determination of in vitro absorption in Caco-2 monolayers of anticancer Ru(II)-based complexes acting as dual human topoisomerase and PARP inhibitors.

de Camargo MS, De Grandis RA, da Silva MM, da Silva PB, Santoni MM, Eismann CE, Menegário AA, Cominetti MR, Zanelli CF, Pavan FR, Batista AA.

Biometals. 2019 Feb;32(1):89-100. doi: 10.1007/s10534-018-0160-0. Epub 2018 Nov 30.

PMID:
30506342
8.

Soluble PD-1 and PD-L1 as potential biomarkers for classical Hodgkin lymphoma.

da Silva PB, Real JM, Ferreira LRP, Esteves GH, Brito FDN, Baiocchi OCG.

Hematol Oncol. 2018 Oct;36(4):709-712. doi: 10.1002/hon.2542. Epub 2018 Aug 26. No abstract available.

PMID:
30146693
9.

Potential of the association of dodecyl gallate with nanostructured lipid system as a treatment for paracoccidioidomycosis: In vitro and in vivo efficacy and toxicity.

Singulani JL, Scorzoni L, Lourencetti NMS, Oliveira LR, Conçolaro RS, da Silva PB, Nazaré AC, Polaquini CR, Victorelli FD, Chorilli M, Regasini LO, Fusco Almeida AM, Mendes Giannini MJS.

Int J Pharm. 2018 Aug 25;547(1-2):630-636. doi: 10.1016/j.ijpharm.2018.06.013. Epub 2018 Jun 6.

PMID:
29883792
10.

NiTi loss on the dentinal walls and instrument deformation during root canal preparation.

Centenaro CF, Grecca FS, Kopper PMP, Vivan RR, Pereira JR, Rosa RAD, da Silva PB, Só MVR.

Microsc Res Tech. 2018 Aug;81(8):897-901. doi: 10.1002/jemt.23053. Epub 2018 May 13.

PMID:
29756274
11.

New 1,2,3-triazole-based analogues of benznidazole for use against Trypanosoma cruzi infection: In vitro and in vivo evaluations.

Leite DI, Fontes FV, Bastos MM, Hoelz LVB, Bianco MDCAD, de Oliveira AP, da Silva PB, da Silva CF, Batista DDGJ, da Gama ANS, Peres RB, Villar JDF, Soeiro MNC, Boechat N.

Chem Biol Drug Des. 2018 Sep;92(3):1670-1682. doi: 10.1111/cbdd.13333. Epub 2018 Jun 13.

PMID:
29745048
12.

Antichagasic, Leishmanicidal, and Trichomonacidal Activity of 2-Benzyl-5-nitroindazole-Derived Amines.

Fonseca-Berzal C, Ibáñez-Escribano A, Vela N, Cumella J, Nogal-Ruiz JJ, Escario JA, da Silva PB, Batista MM, Soeiro MNC, Sifontes-Rodríguez S, Meneses-Marcel A, Gómez-Barrio A, Arán VJ.

ChemMedChem. 2018 Jun 20;13(12):1246-1259. doi: 10.1002/cmdc.201800084. Epub 2018 May 22.

PMID:
29624912
13.

Nanotechnology-based drug delivery systems for control of microbial biofilms: a review.

Dos Santos Ramos MA, Da Silva PB, Spósito L, De Toledo LG, Bonifácio BV, Rodero CF, Dos Santos KC, Chorilli M, Bauab TM.

Int J Nanomedicine. 2018 Feb 27;13:1179-1213. doi: 10.2147/IJN.S146195. eCollection 2018. Review.

14.

Identification of Pyrazolo[3,4-e][1,4]thiazepin based CYP51 inhibitors as potential Chagas disease therapeutic alternative: In vitro and in vivo evaluation, binding mode prediction and SAR exploration.

Ferreira de Almeida Fiuza L, Peres RB, Simões-Silva MR, da Silva PB, Batista DDGJ, da Silva CF, Nefertiti Silva da Gama A, Krishna Reddy TR, Soeiro MNC.

Eur J Med Chem. 2018 Apr 10;149:257-268. doi: 10.1016/j.ejmech.2018.02.020. Epub 2018 Feb 23.

PMID:
29501946
15.

Recent Advances in the Use of Metallic Nanoparticles with Antitumoral Action - Review.

da Silva PB, Machado RTA, Pironi AM, Alves RC, de Araújo PR, Dragalzew AC, Dalberto I, Chorilli M.

Curr Med Chem. 2019;26(12):2108-2146. doi: 10.2174/0929867325666180214102918.

PMID:
29446728
16.

Effect of ethanol on the antimicrobial properties of chlorhexidine over oral biofilm.

Duarte PHM, da Silva PB, Rosa RAD, Montagner F, Duarte MAH, Kuga MC, Só MVR.

Microsc Res Tech. 2018 Apr;81(4):408-412. doi: 10.1002/jemt.22992. Epub 2018 Jan 17.

PMID:
29341381
17.

In Vitro, In Silico, and In Vivo Analyses of Novel Aromatic Amidines against Trypanosoma cruzi.

Santos CC, Lionel JR, Peres RB, Batista MM, da Silva PB, de Oliveira GM, da Silva CF, Batista DGJ, Souza SMO, Andrade CH, Neves BJ, Braga RC, Patrick DA, Bakunova SM, Tidwell RR, Soeiro MNC.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e02205-17. doi: 10.1128/AAC.02205-17. Print 2018 Feb.

18.

In Vitro and In Vivo Studies of the Trypanocidal Effect of Novel Quinolines.

Nefertiti ASG, Batista MM, Da Silva PB, Batista DGJ, Da Silva CF, Peres RB, Torres-Santos EC, Cunha-Junior EF, Holt E, Boykin DW, Brun R, Wenzler T, Soeiro MNC.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e01936-17. doi: 10.1128/AAC.01936-17. Print 2018 Feb.

19.

Design, Synthesis, and Characterization of N-Oxide-Containing Heterocycles with in Vivo Sterilizing Antitubercular Activity.

Dos Santos Fernandes GF, de Souza PC, Moreno-Viguri E, Santivañez-Veliz M, Paucar R, Pérez-Silanes S, Chegaev K, Guglielmo S, Lazzarato L, Fruttero R, Man Chin C, da Silva PB, Chorilli M, Solcia MC, Ribeiro CM, Silva CSP, Marino LB, Bosquesi PL, Hunt DM, de Carvalho LPS, de Souza Costa CA, Cho SH, Wang Y, Franzblau SG, Pavan FR, Dos Santos JL.

J Med Chem. 2017 Oct 26;60(20):8647-8660. doi: 10.1021/acs.jmedchem.7b01332. Epub 2017 Oct 16.

20.

Drug repurposing strategy against Trypanosoma cruzi infection: In vitro and in vivo assessment of the activity of metronidazole in mono- and combined therapy.

Simões-Silva MR, De Araújo JS, Oliveira GM, Demarque KC, Peres RB, D'Almeida-Melo I, Batista DGJ, Da Silva CF, Cardoso-Santos C, Da Silva PB, Batista MM, Bahia MT, Soeiro MNC.

Biochem Pharmacol. 2017 Dec 1;145:46-53. doi: 10.1016/j.bcp.2017.08.025. Epub 2017 Sep 7.

PMID:
28870526
21.

Preventing tissue fibrosis by local biomaterials interfacing of specific cryptic extracellular matrix information.

Horejs CM, St-Pierre JP, Ojala JRM, Steele JAM, da Silva PB, Rynne-Vidal A, Maynard SA, Hansel CS, Rodríguez-Fernández C, Mazo MM, You AYF, Wang AJ, von Erlach T, Tryggvason K, López-Cabrera M, Stevens MM.

Nat Commun. 2017 Jun 8;8:15509. doi: 10.1038/ncomms15509.

22.

Nanostructured lipid carriers for incorporation of copper(II) complexes to be used against Mycobacterium tuberculosis.

Sato MR, Oshiro Junior JA, Machado RT, de Souza PC, Campos DL, Pavan FR, da Silva PB, Chorilli M.

Drug Des Devel Ther. 2017 Mar 20;11:909-921. doi: 10.2147/DDDT.S127048. eCollection 2017.

23.

High OCT4A levels drive tumorigenicity and metastatic potential of medulloblastoma cells.

da Silva PBG, Teixeira Dos Santos MC, Rodini CO, Kaid C, Pereira MCL, Furukawa G, da Cruz DSG, Goldfeder MB, Rocha CRR, Rosenberg C, Okamoto OK.

Oncotarget. 2017 Mar 21;8(12):19192-19204. doi: 10.18632/oncotarget.15163.

24.

New antimycobacterial agents in the pre-clinical phase or beyond: recent advances in patent literature (2001-2016).

da Silva PB, Campos DL, Ribeiro CM, da Silva IC, Pavan FR.

Expert Opin Ther Pat. 2017 Mar;27(3):269-282. doi: 10.1080/13543776.2017.1253681. Epub 2016 Nov 11. Review.

PMID:
27796146
25.

Nanotechnology-Based Drug Delivery Systems for Treatment of Tuberculosis--A Review.

da Silva PB, de Freitas ES, Bernegossi J, Gonçalez ML, Sato MR, Leite CQ, Pavan FR, Chorilli M.

J Biomed Nanotechnol. 2016 Feb;12(2):241-60. Review.

PMID:
27305759
26.

Phenotypic Screening In Vitro of Novel Aromatic Amidines against Trypanosoma cruzi.

Simões-Silva MR, Nefertiti AS, De Araújo JS, Batista MM, Da Silva PB, Bahia MT, Menna-Barreto RS, Pavão BP, Green J, Farahat AA, Kumar A, Boykin DW, Soeiro MN.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):4701-7. doi: 10.1128/AAC.01788-15. Print 2016 Aug.

27.

Synthesis and preliminary evaluation of 3-thiocyanato-1H-indoles as potential anticancer agents.

Fortes MP, da Silva PB, da Silva TG, Kaufman TS, Militão GC, Silveira CC.

Eur J Med Chem. 2016 Aug 8;118:21-6. doi: 10.1016/j.ejmech.2016.04.039. Epub 2016 Apr 19.

PMID:
27116711
28.

Antichagasic and trichomonacidal activity of 1-substituted 2-benzyl-5-nitroindazolin-3-ones and 3-alkoxy-2-benzyl-5-nitro-2H-indazoles.

Fonseca-Berzal C, Ibáñez-Escribano A, Reviriego F, Cumella J, Morales P, Jagerovic N, Nogal-Ruiz JJ, Escario JA, da Silva PB, Soeiro Mde N, Gómez-Barrio A, Arán VJ.

Eur J Med Chem. 2016 Jun 10;115:295-310. doi: 10.1016/j.ejmech.2016.03.036. Epub 2016 Mar 17.

PMID:
27017556
29.

In Vitro and In Vivo Trypanosomicidal Action of Novel Arylimidamides against Trypanosoma cruzi.

Guedes-da-Silva FH, Batista DG, Meuser MB, Demarque KC, Fulco TO, Araújo JS, Da Silva PB, Da Silva CF, Patrick DA, Bakunova SM, Bakunov SA, Tidwell RR, Oliveira GM, Britto C, Moreira OC, Soeiro MN.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2425-34. doi: 10.1128/AAC.01667-15. Print 2016 Apr.

30.

A Nanostructured Lipid System as a Strategy to Improve the in Vitro Antibacterial Activity of Copper(II) Complexes.

da Silva PB, Bonifácio BV, Frem RC, Godoy Netto AV, Mauro AE, Ferreira AM, Lopes Ede O, Raddi MS, Bauab TM, Pavan FR, Chorilli M.

Molecules. 2015 Dec 16;20(12):22534-45. doi: 10.3390/molecules201219822.

31.

Nanostructured lipid system as a strategy to improve the anti-Candida albicans activity of Astronium sp.

Bonifácio BV, Ramos MA, da Silva PB, Negri KM, de Oliveira Lopes É, de Souza LP, Vilegas W, Pavan FR, Chorilli M, Bauab TM.

Int J Nanomedicine. 2015 Aug 10;10:5081-92. doi: 10.2147/IJN.S79684. eCollection 2015.

32.

Imbalance of Pro- and Anti-Inflammatory Cytokines in Patients With cHL Persists Despite Treatment Compared With Control Subjects.

da Silva PB, Perini GF, Pereira Lde A, Sacconato EM, Penna AM, Garibaldi J, Cavalcante E, Baiocchi OC.

Clin Lymphoma Myeloma Leuk. 2015 Jun;15 Suppl:S151-7. doi: 10.1016/j.clml.2015.02.002.

PMID:
26297269
33.

Nanotechnological strategies for vaginal administration of drugs--a review.

da Silva PB, Ramos MA, Bonifácio BV, Negri KM, Sato MR, Bauab TM, Chorilli M.

J Biomed Nanotechnol. 2014 Sep;10(9):2218-43. Review.

PMID:
25992455
34.

Recent advances in nanoparticle carriers for coordination complexes.

Sato MR, da Silva PB, de Souza RA, dos Santos KC, Chorilli M.

Curr Top Med Chem. 2015;15(4):287-97. Review.

PMID:
25579344
35.

Reading component skills in dyslexia: word recognition, comprehension and processing speed.

de Oliveira DG, da Silva PB, Dias NM, Seabra AG, Macedo EC.

Front Psychol. 2014 Nov 28;5:1339. doi: 10.3389/fpsyg.2014.01339. eCollection 2014.

36.

Antimicrobial activity of natural products against Helicobacter pylori: a review.

Bonifácio BV, dos Santos Ramos MA, da Silva PB, Bauab TM.

Ann Clin Microbiol Antimicrob. 2014 Nov 19;13:54. doi: 10.1186/s12941-014-0054-0. Review.

37.

Strength training associated with task-oriented training to enhance upper-limb motor function in elderly patients with mild impairment after stroke: a randomized controlled trial.

da Silva PB, Antunes FN, Graef P, Cechetti F, Pagnussat Ade S.

Am J Phys Med Rehabil. 2015 Jan;94(1):11-9. doi: 10.1097/PHM.0000000000000135.

PMID:
25122097
38.

Nanostructured lipid systems as a strategy to improve the in vitro cytotoxicity of ruthenium(II) compounds.

de Freitas ES, da Silva PB, Chorilli M, Batista AA, de Oliveira Lopes E, da Silva MM, Leite CQ, Pavan FR.

Molecules. 2014 May 9;19(5):5999-6008. doi: 10.3390/molecules19055999.

39.

In vitro and in vivo biological effects of novel arylimidamide derivatives against Trypanosoma cruzi.

Timm BL, da Silva PB, Batista MM, da Silva FH, da Silva CF, Tidwell RR, Patrick DA, Jones SK, Bakunov SA, Bakunova SM, Soeiro Mde N.

Antimicrob Agents Chemother. 2014 Jul;58(7):3720-6. doi: 10.1128/AAC.02353-14. Epub 2014 Apr 21.

40.

In vitro investigation of the efficacy of novel diamidines against Trypanosoma cruzi.

Timm BL, Da Silva PB, Batista MM, Farahat AA, Kumar A, Boykin DW, Soeiro MN.

Parasitology. 2014 Sep;141(10):1272-6. doi: 10.1017/S0031182014000407. Epub 2014 Apr 15.

PMID:
24735493
41.

In vitro and in vivo studies of the biological activity of novel arylimidamides against Trypanosoma cruzi.

De Araújo JS, Da Silva CF, Batista DG, Da Silva PB, Meuser MB, Aiub CA, da Silva MF, Araújo-Lima CF, Banerjee M, Farahat AA, Stephens CE, Kumar A, Boykin DW, Soeiro MN.

Antimicrob Agents Chemother. 2014 Jul;58(7):4191-5. doi: 10.1128/AAC.01403-13. Epub 2014 Mar 3.

42.

Synthesis and evaluation of (-)-Massoialactone and analogues as potential anticancer and anti-inflammatory agents.

Barros ME, Freitas JC, Oliveira JM, da Cruz CH, da Silva PB, de Araújo LC, Militão GC, da Silva TG, Oliveira RA, Menezes PH.

Eur J Med Chem. 2014 Apr 9;76:291-300. doi: 10.1016/j.ejmech.2014.02.013. Epub 2014 Feb 11.

PMID:
24589485
43.

Effects of genistein and daidzein on cell proliferation kinetics in HT29 colon cancer cells: the expression of CTNNBIP1 (β-catenin), APC (adenomatous polyposis coli) and BIRC5 (survivin).

Lepri SR, Zanelatto LC, da Silva PB, Sartori D, Ribeiro LR, Mantovani MS.

Hum Cell. 2014 Apr;27(2):78-84. doi: 10.1007/s13577-012-0051-6. Epub 2014 Jan 4.

PMID:
24390805
44.

Activities of psilostachyin A and cynaropicrin against Trypanosoma cruzi in vitro and in vivo.

da Silva CF, Batista Dda G, De Araújo JS, Batista MM, Lionel J, de Souza EM, Hammer ER, da Silva PB, De Mieri M, Adams M, Zimmermann S, Hamburger M, Brun R, Schühly W, Soeiro Mde N.

Antimicrob Agents Chemother. 2013 Nov;57(11):5307-14. doi: 10.1128/AAC.00595-13. Epub 2013 Aug 12.

45.

In vitro and in vivo studies of the antiparasitic activity of sterol 14α-demethylase (CYP51) inhibitor VNI against drug-resistant strains of Trypanosoma cruzi.

Soeiro Mde N, de Souza EM, da Silva CF, Batista Dda G, Batista MM, Pavão BP, Araújo JS, Aiub CA, da Silva PB, Lionel J, Britto C, Kim K, Sulikowski G, Hargrove TY, Waterman MR, Lepesheva GI.

Antimicrob Agents Chemother. 2013 Sep;57(9):4151-63. doi: 10.1128/AAC.00070-13. Epub 2013 Jun 17.

46.

Chemoprotective activity of the isoflavones, genistein and daidzein on mutagenicity induced by direct and indirect mutagens in cultured HTC cells.

Lepri SR, Luiz RC, Zanelatto LC, da Silva PB, Sartori D, Ribeiro LR, Mantovani MS.

Cytotechnology. 2013 Mar;65(2):213-22. doi: 10.1007/s10616-012-9476-8. Epub 2012 Jun 30.

47.

Copper(II)-fluoroquinolone complexes with anti-Trypanosoma cruzi activity and DNA binding ability.

Martins DA, Gouvea LR, da Gama Jean Batista D, da Silva PB, Louro SR, de Nazaré C Soeiro M, Teixeira LR.

Biometals. 2012 Oct;25(5):951-60. doi: 10.1007/s10534-012-9565-3. Epub 2012 Jun 10.

PMID:
22684240
48.

In vitro and in vivo investigation of the efficacy of arylimidamide DB1831 and its mesylated salt form--DB1965--against Trypanosoma cruzi infection.

da Silva CF, Batista Dda G, Oliveira GM, de Souza EM, Hammer ER, da Silva PB, Daliry A, Araujo JS, Britto C, Rodrigues AC, Liu Z, Farahat AA, Kumar A, Boykin DW, Soeiro Mde N.

PLoS One. 2012;7(1):e30356. doi: 10.1371/journal.pone.0030356. Epub 2012 Jan 23.

49.

The efficacy of novel arylimidamides against Trypanosoma cruzi in vitro.

DA Silva CF, Daliry A, DA Silva PB, Akay S, Banerjee M, Farahat AA, Fisher MK, Hu L, Kumar A, Liu Z, Stephens CE, Boykin DW, Correia Soeiro MD.

Parasitology. 2011 Dec;138(14):1863-9. doi: 10.1017/S0031182011001429. Epub 2011 Sep 9.

PMID:
21902869
50.

Uric acid levels are associated with microvascular endothelial dysfunction in patients with Type 1 diabetes.

Matheus AS, Tibiriçá E, da Silva PB, de Fátima Bevilácqua da Matta M, Gomes MB.

Diabet Med. 2011 Oct;28(10):1188-93. doi: 10.1111/j.1464-5491.2011.03349.x.

PMID:
21658123

Supplemental Content

Loading ...
Support Center